TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03731390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR1405 injection
Description: Intravenous administration according to the patient's weight. All dose groups were administered once every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR1405 injection
Description: Intravenous administration according to the patient's weight. All dose groups were administered once every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR1405 injection
Description: Intravenous administration according to the patient's weight. All dose groups were administered once every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR1405 injection
Description: Intravenous administration according to the patient's weight. All dose groups were administered once every 2 weeks.
Study: NCT04685642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin (100mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin (20mg/day)
Study: NCT02169843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: inhale Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: inhale Sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: intravenous pumping Dexmedetomidine 0.2µg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for Dexmedetomidine)
Description: normal saline mimic Dexmedetomidine, intravenous pumping 0.05ml/kg/h
Study: NCT01916460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)
Description: After the subjects meet the criteria for enrollment in the study, gastroparetic patients will undergo linear EUS examination of the stomach wall one day prior to their surgery to obtain single or multiple core biopsies of the stomach body wall using the 19-gauge core biopsy needle under EUS guidance. The pathologist will be in the room to assess the adequacy of the sample after each pass. Once the pathologist deemed that the obtained sample is sufficient, the procedure will be terminated
Study: NCT01871077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-156
Description: Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
Study: NCT02716584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Veterans in the physical exercise group will participate in a 12-week, instructor-led, outdoor brisk walking exercise program conducted in small groups, held 3 times per week, gradually increasing walking time until reaching a maximum of 40-minutes per session. The heart rate of each Veteran will be monitored during the walking sessions to help ensure maintenance of a target peak heart rate of 60% to 70% of the maximum for the individual's age (i.e., 220-age).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise
Description: Veterans in the control condition will participate in instructor-led, non-aerobic stretching exercises conducted in small groups, held 3 times per week.
Study: NCT00585338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem 532/1064 nm Laser
Description: Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser
Study: NCT02787122

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-E
Description: Patients receive 25 sessions of individual emotion-focused Cognitive Behavior Therapy based on a manual. Interventions aim on patients' mood by implementing positive activities in their daily routine. Further, patients train to reduce worrying behavior. Social contacts are fostered as well. Later, patients are informed on emotions and train emotion regulation strategies. Finally, the focus of CBT-E is on self-acceptance.Patients receive psychoeducation on self-acceptance and learn strategies in order to reduce negative self-schema and foster positive self-schema.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Patients receive standardized treatment. After a waiting period of six month, patients receive CBT-E
Study: NCT06361186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proximod
Description: Single and multiple-dose to establish the safety and PK profile

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo controlled
Study: NCT02951624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Control intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaker
Description: Short breaks of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonger
Description: longer breaks of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermediate
Description: Intermediate breaks of physical activity
Study: NCT01858207

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter Arterial Chemoembolization
Description: traditional TACE, conventional TACE

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: simultaneous multiple electrodes and switching RF controller

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: TACE will be done according to the current method in our center. We use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
Study: NCT03643302

Intervention type: DEVICE
Intervention: Version BF-1T26 electronic bronchoscope
Description: Interventions involving the therapy of airway clearance and bronchoalveolar lavage by Version BF-1T26 electronic bronchoscope
Study: NCT02732288

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: After measuring the subject's own timing of release of melatonin, subjects will be provided a dose of melatonin at 8pm to test the effects on the electrical activity of sleep, measured using electroencephalography. The same intervention will be given to healthy, non-brain injured controls.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: After measuring the subject's own timing of release of melatonin, subjects will be provided a dose of melatonin at 8pm to test the effects on the electrical activity of sleep, measured using electroencephalography. The same intervention will be given to healthy, non-brain injured controls.
Study: NCT02497508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Study: NCT02273362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00805129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus (RAD001) is a novel oral derivative of rapamycin. Everolimus will be administered orally as a once-daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take Everolimus in the morning, at the same time each day. Everolimus should be taken by the patient in a fasting state or with no more than a light fat-free meal.
Study: NCT01829698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tauroursodeoxycholic
Description: Testing arm: tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ursodeoxycholic acid
Description: ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
Study: NCT02601222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Runzao zhiyang capsule
Description: Runzao zhiyang capsule：4 pills each time, 3 times a day, oral. Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Runzaozhiyang capsule agent simulation
Description: Runzaozhiyang capsule agent simulation：4 pills each time, 3 times a day, oral， Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea cream
Description: Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Urea cream
Description: Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
Study: NCT01938846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 860585
Description: BI 860585 multiple dose escalation, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: exemestane once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 860585
Description: BI 860585 multiple dose escalation, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 860585
Description: BI 860585 multiple dose escalation, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel once weekly
Study: NCT02775097

Intervention type: DEVICE
Intervention: OCT
Description: OCT for all Arms

Intervention type: DEVICE
Intervention: OCT
Description: OCT for all Arms
Study: NCT00696735

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: injection cyclophosphamide doxorubicin (25 mg/m2), and teniposide (60 mg/m2)(600 mg/m2)on day 1 and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high dose therapy and autologous stem cell transplantation
Description: VCAP regimen 3 cycles , less than PR: 2-3 DHAP, stem cell collection, in vitro purging autologous stem cell transplantation with TBI and cyclophosphamide
Study: NCT01007370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: Tracheal intubation through a supraglottic airway device(LMA-Fastrach).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: Tracheal intubation through a supraglottic airway device(I-gel).
Study: NCT04258124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control motor intervention
Description: The intervention through motor control will consist in the application of the protocol described by Hidalgo-Peréz et al. The objective of the application of the technique is to produce an increase in the strength of the deep cervical musculature. The exercises will be performed with the subject in different positions: supine, quadrupedic and standing position. The physiotherapist will be placed in standing position in front of the subject. The intervention will be carried out in 3 sessions with 3 exercises of 15 repetitions, and with breaks of 40 seconds between each series and exercise.
Study: NCT01634503

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GX-188E administered by electroporation
Description: Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GX-188E administered by electroporation
Description: Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GX-188E administered by electroporation
Description: Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
Study: NCT04551664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best medical management
Description: All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best medical management
Description: All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Description: In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy (recommended with Solitaire、EMBOTRAP、Trevo or Reco revascularization device) or aspiration thrombectomy (recommended with Penumbra) will be recommended as the primary treatment.
Study: NCT03651817

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation
Description: Patients will be ventilated with anesthesia machine according to the group they belong to

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation
Description: Patients will be ventilated with anesthesia machine according to the group they belong to
Study: NCT01833585

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cell
Description: Peripheral blood mononuclear cell solution 59 cc will be injected to the gastrocnemius muscle of ischemic limb of patients with critical limb ischemia
Study: NCT02810275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Folinic acid 5 mg, taking in the morning, daily, during four weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule received 1 tablet, taking in the morning, during four weeks
Study: NCT01655095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: PEG 2L at 1800hrs the night before the test and 2L at 0500hrs the morning of the test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride 2mg will be administered at 0800hrs on the day of the test, at the same time the colon capsule is administered. Two hours later the position of the colon capsule will be assess with a Realtime Viewer. If the capsule has not reached the cecum a second dose of Prucalopride 2mg will be administered at that time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride 2mg will be administered at 0800hrs on the day of the test, at the same time the colon capsule is administered. Two hours later the position of the colon capsule will be assess with a Realtime Viewer. If the capsule has not reached the cecum a second dose of Prucalopride 2mg will be administered at that time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picosalax
Description: One sachet at 1800hrs the night before the test One sachet at 0500hrs the day of the test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Description: Bisacodyl 10mg in the evening three nights before the procedure and 10mg again two nights before the procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon capsule
Description: The colon capsule will be ingested at 0800hrs the day of the test. Seven hours will be allowed for the capsule to clear the bowel. The images will be reviewed by two endoscopists with experience reading video capsule endoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon capsule
Description: The colon capsule will be ingested at 0800hrs the day of the test. Seven hours will be allowed for the capsule to clear the bowel. The images will be reviewed by two endoscopists with experience reading video capsule endoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: At 1500hrs on the day of the test all individuals will return to the endoscopy unit for a colonoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: At 1500hrs on the day of the test all individuals will return to the endoscopy unit for a colonoscopy.
Study: NCT03097432

Intervention type: DRUG
Intervention: ORALVAC COMPACT BÄUME
Study: NCT01345812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HP-HMG
Description: 100 - 300 IU for stimulation of women in ART treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Description: 100 -300 IU for stimulation of women in ART treatment
Study: NCT01388153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose (Glucobay ODT, BAYG5421)
Description: Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose (Glucobay ODT, BAYG5421)
Description: Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken with water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose (Glucobay, BAYG5421)
Description: Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet; Day 2: oral sucrose load plus Glucobay standard tablet taken with water
Study: NCT04988334

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait Control
Description: usual activities

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wait Control
Description: usual activities
Study: NCT04118647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wu-Chu-Yu tang
Description: Wu-Chu-Yu tang at a rate of 3.0 g three times per day for 28 days.
Study: NCT03969615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SuperNO2VA nasal positive airway pressure devic
Description: SuperNO2VA nasal positive airway pressure device utilizes supplemental oxygen and an adjustable pressure limiting valve to maintain upper airway latency

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental oxygen
Description: 5lpm of supplemental oxygen
Study: NCT03876483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual peer support group
Description: Intervention package will consist of a WhatsApp group setup and organized by the study. Participants will be divided into 1-3 WhatsApp groups, each with 10-55 youth. Each group will be facilitated by a study staff member trained as a counselor. The facilitator will send weekly messages to the group. Messages from the facilitator will not contain overtly HIV-related language. These messages are intended to spark unstructured discussion among study participants, or with the facilitator, at any time through the WhatsApp group or individually. Subsequent messages from the study will answer participant questions or correct misinformation. Standard operating procedures (SOPs) will be developed for standardizing responses to the questions received so that study staff follow national guidelines and local practice standards to respond.
Study: NCT01070433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEBO Wound Ointment (MEBO)
Description: Topical application twice a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Topical application twice a day
Study: NCT00674206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m\^2 on day 1 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 100mg/m\^2 on day 2 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
Study: NCT02010112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath Test Collection bags
Description: Breath Collection bags will be used to collect breath of subjects before and after ingestion of 13-C breath test substrate
Study: NCT03562858

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate dentin sealing protocol
Description: Sealing of the dentin before impression taking directly after cavity preparation to prevent postoperative hypersensitivity during provisionalization and after cementation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed dentin sealing protocol
Description: Sealing the dentin just prior to cementation
Study: NCT03285945

Intervention type: DRUG
Intervention: PET3
Description: Prednisolone 60 mg daily for 3 days

Intervention type: DRUG
Intervention: PET10
Description: Prednisolone 60 mg daily for 10 days
Study: NCT04298580

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVB block
Description: PVB block before surgery versus after surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVB block
Description: PVB block before surgery versus after surgery
Study: NCT03560869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal hydration
Description: see description in 'arms'

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal hydration
Description: see description in 'arms'

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dehydration
Description: see description in 'arms'

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dehydration
Description: see description in 'arms'